The use of redox manipula ons in the manufacture of ac ve pharmaceu cal ingredients (APIs) is o en avoided due to the large amounts of chemical waste generated for a transforma on that doesn't significantly increase the molecular complexity. Moreover, many stoichiometric oxidants and reductants can pose serious safety risks and/or complicate downstream isola ons. Replacing hazardous, mass-inefficient oxidants/reductants with controlled electrochemical reac ons will enable more versa le design of API syntheses and engage renewable feedstocks. Alterna vely, electrochemically genera ng hazardous reagents in flow could be a viable strategy for mi ga ng the safety concerns associated with these reagents. Despite the obvious advantages that electrochemical reac ons provide, synthe c organic electrochemistry has been largely unrealized in the pharmaceu cal space. The lack of pharmaceu cal applica ons is due to insufficient infrastructure for execu ng electrochemical reac ons at scale. While, electrochemical reac ons have been demonstrated on an industrial scale, these examples have primarily u lized very large footprint electrochemical plants for produc on of a single commodity chemical (e.g. Monsanto adiponitrile process) and u lized highly op mized electrode materials. The development of a rapidly deployable, more modular, low-footprint reactor design is necessary for widespread adop on of electrochemistry in the pharmaceu cal industry.